Vericel Förvaltning
Förvaltning kriterier kontrolleras 3/4
Vericel VD är Nick Colangelo, utsedd i Mar 2013, har en mandatperiod på 13.42 år. totala årliga ersättningen är $ 11.16M, bestående av 7.7% lön 92.3% bonusar, inklusive företagsaktier och optioner. äger direkt 0.61% av företagets aktier, värda $ 13.63M. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 4.9 år respektive 13.4 år.
Viktig information
Nick Colangelo
Verkställande direktör
US$11.2m
Total ersättning
| VD-lön i procent | 7.71% |
| Anställning som VD | 13.4yrs |
| Ägande av VD | 0.6% |
| Ledningens genomsnittliga anställningstid | 4.9yrs |
| Styrelsens genomsnittliga mandatperiod | 13.4yrs |
Senaste uppdateringar av ledningen
Recent updates
Uppdatering av berättelse • Jul 31
VCEL: Raised Guidance And Buyback Will Support Stronger Forward Repricing
Analysts have raised their fair value estimate for Vericel stock from $42.00 to $55.00, citing recent price target increases that follow reported MACI performance in Q2, as well as guidance they consider achievable for the second half of the year. Analyst Commentary Recent Street research on Vericel has focused on how current expectations for MACI and the broader MedTech backdrop feed into risk and reward for the stock.
Uppdatering av berättelse • Jul 17
VCEL: Raised Outlook And New Headquarters Will Support Stronger Future Position
Vericel's implied fair value estimate has moved from about $53.88 to $57.14 as analysts adjust their price targets, citing updated expectations around revenue growth, profit margins and sector volatility. What’s in the News for Vericel Vericel approved an amendment to the company’s bylaws to reflect the relocation of its principal executive offices to a new global headquarters at 25 Blue Sky Drive, Burlington, Massachusetts 01803.
Uppdatering av berättelse • Jun 26
VCEL: Strong Q1 Execution And BARDA Contract Will Drive Future Upside
Analysts have raised their fair value estimate for Vericel to $70.00 from $64.00, citing updated assumptions on revenue growth, profit margins, and future P/E, even as some Street targets such as Truist's have recently moved lower. What’s in the News for Vericel Analysts highlighted Vericel’s recent first quarter results, where revenues were reported at 7.6% above expectations and statutory losses were reduced, according to a summary of Wall Street research (source: Zacks / TD Cowen coverage summary).Analysartikel • Jun 22
Vericel (VCEL) Stock Could Be 37.3% Undervalued After Earnings Beat And Fund Buying
Vericel (VCEL) has drawn fresh attention after institutional holders such as BlackRock and State Street lifted their positions, and the company reported quarterly earnings per share that came in above market expectations. See our latest analysis for Vericel. Vericel's share price has picked up momentum recently, with a 1-day share price return of 2.48%, 7-day return of 7.05%, and 90-day return of 23.57%. This comes even though the 1-year total shareholder return declined 4.57% and the 5-year...Analysartikel • May 09
The Vericel Corporation (NASDAQ:VCEL) First-Quarter Results Are Out And Analysts Have Published New Forecasts
As you might know, Vericel Corporation ( NASDAQ:VCEL ) just kicked off its latest quarterly results with some very...Ny berättelse • May 02
Expanded Cell Therapy Capacity And Burn Care Franchise Will Drive Multiyear Upside Potential
Catalysts About Vericel Vericel develops and manufactures advanced cell therapies for cartilage repair and severe burn care. What are the underlying business or industry changes driving this perspective?Ny berättelse • Apr 17
Expanded Cell Therapy Pipeline Will Face Execution Risks Yet Ultimately Support Healthier Business
Catalysts About Vericel Vericel develops and manufactures advanced cell therapies for sports medicine and burn care, including MACI for cartilage repair and Epicel and NexoBrid in burn care. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Jan 04
Vericel: Growth Plans May Have Run Out Of Gas (Rating Downgrade)
Summary Vericel (VCEL) is rated a hold due to inconsistent growth, fluctuating profitability, and limited near-term upside at current valuation. VCEL’s future hinges on scaling MACI, as Epicel and Nexobrid have stalled and face capped demand in niche markets. International expansion and MACI Arthro could drive growth, but execution risks and delayed timelines temper confidence in acceleration. Despite strong cash and no long-term debt, persistent SG&A growth and negative free cash flow highlight challenges in achieving sustainable profitability. Read the full article on Seeking AlphaAnalysartikel • Nov 12
There's No Escaping Vericel Corporation's (NASDAQ:VCEL) Muted Revenues Despite A 29% Share Price Rise
Vericel Corporation ( NASDAQ:VCEL ) shares have had a really impressive month, gaining 29% after a shaky period...Analysartikel • Jun 16
Does Vericel (NASDAQ:VCEL) Deserve A Spot On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analysartikel • May 01
Risks To Shareholder Returns Are Elevated At These Prices For Vericel Corporation (NASDAQ:VCEL)
With a median price-to-sales (or "P/S") ratio of close to 9.6x in the Biotechs industry in the United States, you could...Seeking Alpha • Mar 06
Vericel: Scalable Growth With Strong Margins
Summary Vericel's niche in regenerative medicine is undervalued, with FDA-approved products like MACI, Epicel, and NexoBrid driving steady revenue growth and profitability. The company's strong financials include $167 million in cash, zero debt, and a 16% year-over-year revenue increase, highlighting operational efficiency. MACI's expansion into ankle cartilage repair and a robust pipeline suggest significant future earnings potential, despite current market hesitations. VCEL's strategy focuses on indication expansion and market penetration, aiming for long-term margin growth and reduced vulnerability to high-risk drug development. Read the full article on Seeking AlphaSeeking Alpha • Dec 19
Vericel Corporation: Hard To Justify Current Valuation
Summary Vericel Corporation, specializing in cellular therapies for sports medicine and severe burn care, has seen a 40% rise in its stock recently. Core products include MACI, NexoBrid, and Epicel, with Q3 revenues rising 27% year-over-year to $57.9 million, beating expectations. The company is turning the corner on profitability, but valuations look stretched at current trading levels. An analysis around Vericel follows in the paragraphs below. Read the full article on Seeking AlphaAnalysartikel • Nov 09
Vericel Corporation (NASDAQ:VCEL) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected
Vericel Corporation ( NASDAQ:VCEL ) shares have had a really impressive month, gaining 32% after a shaky period...
Ny berättelse • Sep 10
MACI And NexoBrid Drive Record Revenues And Profit Growth, Setting Stage For Robust Future Performance
Expansion of MACI and NexoBrid markets driving record revenues, indicating significant future revenue growth.Analysartikel • Jul 12
What Vericel Corporation's (NASDAQ:VCEL) P/S Is Not Telling You
With a median price-to-sales (or "P/S") ratio of close to 11.3x in the Biotechs industry in the United States, you...Analysartikel • May 11
Vericel Corporation (NASDAQ:VCEL) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Vericel Corporation ( NASDAQ:VCEL ) just released its first-quarter report and things are looking bullish. Revenues and...Analysartikel • Apr 26
It's Unlikely That The CEO Of Vericel Corporation (NASDAQ:VCEL) Will See A Huge Pay Rise This Year
Key Insights Vericel will host its Annual General Meeting on 1st of May Salary of US$790.0k is part of CEO Nick...Analysartikel • Mar 02
Is There An Opportunity With Vericel Corporation's (NASDAQ:VCEL) 49% Undervaluation?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Vericel fair value estimate is US$87.12 Vericel is estimated...Analysartikel • Feb 02
Revenues Not Telling The Story For Vericel Corporation (NASDAQ:VCEL) After Shares Rise 29%
Vericel Corporation ( NASDAQ:VCEL ) shareholders would be excited to see that the share price has had a great month...Analysartikel • May 05
Vericel Corporation's (NASDAQ:VCEL) Shareholders Might Be Looking For Exit
It's not a stretch to say that Vericel Corporation's ( NASDAQ:VCEL ) price-to-sales (or "P/S") ratio of 9.4x right now...Analys av ersättningar till VD
| Datum | Total ersättning | Lön | Företagets resultat |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | US$24m |
| Mar 31 2026 | n/a | n/a | US$21m |
| Dec 31 2025 | US$11m | US$860k | US$17m |
| Sep 30 2025 | n/a | n/a | US$13m |
| Jun 30 2025 | n/a | n/a | US$7m |
| Mar 31 2025 | n/a | n/a | US$3m |
| Dec 31 2024 | US$10m | US$830k | US$10m |
| Sep 30 2024 | n/a | n/a | US$4m |
| Jun 30 2024 | n/a | n/a | US$789k |
| Mar 31 2024 | n/a | n/a | US$451k |
| Dec 31 2023 | US$7m | US$790k | -US$3m |
| Sep 30 2023 | n/a | n/a | -US$10m |
| Jun 30 2023 | n/a | n/a | -US$13m |
| Mar 31 2023 | n/a | n/a | -US$17m |
| Dec 31 2022 | US$9m | US$760k | -US$17m |
| Sep 30 2022 | n/a | n/a | -US$18m |
| Jun 30 2022 | n/a | n/a | -US$16m |
| Mar 31 2022 | n/a | n/a | -US$11m |
| Dec 31 2021 | US$13m | US$730k | -US$7m |
| Sep 30 2021 | n/a | n/a | US$214k |
| Jun 30 2021 | n/a | n/a | US$9m |
| Mar 31 2021 | n/a | n/a | US$4m |
| Dec 31 2020 | US$4m | US$675k | US$3m |
| Sep 30 2020 | n/a | n/a | US$145k |
| Jun 30 2020 | n/a | n/a | -US$3k |
| Mar 31 2020 | n/a | n/a | -US$12m |
| Dec 31 2019 | US$5m | US$634k | -US$10m |
Ersättning vs marknad: Nick s total kompensation ($USD 11.16M ) är över genomsnittet för företag av liknande storlek på US marknaden ($USD 5.18M ).
Ersättning vs inkomst: Ersättningen från Nick har varit i linje med företagets resultat under det senaste året.
VD OCH KONCERNCHEF
Nick Colangelo (62 yo)
13.4yrs
Anställning
US$11,156,368
Kompensation
Mr. Dominick C. Colangelo, also known as Nick, Esq., has been the Chief Executive Officer and President at Vericel Corporation since March 1, 2013 and served as its Treasurer since May 7, 2014. He has been...
Ledningsgrupp
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| CEO, President & Director | 13.4yrs | US$11.16m | 0.61% $ 13.6m | |
| CFO & Treasurer | 5.6yrs | US$3.24m | 0.031% $ 697.4k | |
| Chief Operating Officer | 7.2yrs | US$3.62m | 0.032% $ 714.4k | |
| Chief Legal Officer | 6.8yrs | US$2.55m | 0.0032% $ 71.8k | |
| Chief Medical Officer | 8yrs | US$2.56m | 0.15% $ 3.3m | |
| Principal Accounting Officer | 4.5yrs | inga uppgifter | 0.0021% $ 47.1k | |
| Vice President of Finance & Investor Relations | no data | inga uppgifter | inga uppgifter | |
| Chief Marketing Officer | 1.6yrs | inga uppgifter | inga uppgifter | |
| Senior Vice President of Corporate Development & Strategy | 4.9yrs | inga uppgifter | inga uppgifter | |
| Senior Vice President of Sales | 2.6yrs | inga uppgifter | inga uppgifter | |
| Chief Human Resources Officer | 2.1yrs | US$3.21m | 0.0036% $ 80.8k | |
| Senior Vice President of Operations | 4.5yrs | inga uppgifter | inga uppgifter |
4.9yrs
Genomsnittlig anställningstid
57.5yo
Genomsnittlig ålder
Erfaren ledning: VCEL s ledningsgrupp anses vara erfaren ( 4.9 års genomsnittlig anställningstid).
Styrelseledamöter
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| CEO, President & Director | 13.4yrs | US$11.16m | 0.61% $ 13.6m | |
| Independent Director | 11.6yrs | US$357.80k | 0.036% $ 797.4k | |
| Independent Director | 11.6yrs | US$348.43k | 0.037% $ 819.2k | |
| Independent Chairman & Lead Director | 20.6yrs | US$395.30k | 0.064% $ 1.4m | |
| Independent Director | 20.9yrs | US$365.30k | 0.13% $ 2.8m | |
| Member of Scientific Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Member of Scientific Advisory Board | 16.3yrs | inga uppgifter | inga uppgifter | |
| Member of Scientific Advisory Board | 16.3yrs | inga uppgifter | inga uppgifter | |
| Independent Director | 13yrs | US$355.30k | 0.068% $ 1.5m | |
| Independent Director | 5.2yrs | US$342.80k | 0.031% $ 690.5k |
13.4yrs
Genomsnittlig anställningstid
65.5yo
Genomsnittlig ålder
Erfaren styrelse: VCEL s styrelse är rutinerade och erfaren ( 13.4 års genomsnittlig mandatperiod).
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/08/20 06:44 |
| Aktiekurs vid dagens slut | 2026/08/20 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Vericel Corporation bevakas av 20 analytiker. 8 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Keay Nakae | Ascendiant Capital Markets LLC |
| Michael Gorman | BTIG |
| Caitlin Cronin | Canaccord Genuity |